Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9286966rdf:typepubmed:Citationlld:pubmed
pubmed-article:9286966lifeskim:mentionsumls-concept:C0042510lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0149721lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C1522565lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0006938lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0679109lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0684321lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0001272lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C0332624lld:lifeskim
pubmed-article:9286966lifeskim:mentionsumls-concept:C2926735lld:lifeskim
pubmed-article:9286966pubmed:issue4lld:pubmed
pubmed-article:9286966pubmed:dateCreated1997-9-22lld:pubmed
pubmed-article:9286966pubmed:abstractTextLeft ventricular hypertrophy (LVH) is associated with multiple cellular electrophysiological abnormalities, susceptibility to ventricular arrhythmias, and an increased risk of sudden death. Several pharmacological therapies have been shown to produce regression of hypertrophy, but the value of regression is unclear. The present study examines whether pharmacological regression of LVH has effects on the susceptibility to ventricular arrhythmia or the cellular electrophysiological abnormalities of LVH.lld:pubmed
pubmed-article:9286966pubmed:languageenglld:pubmed
pubmed-article:9286966pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9286966pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9286966pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9286966pubmed:statusMEDLINElld:pubmed
pubmed-article:9286966pubmed:monthAuglld:pubmed
pubmed-article:9286966pubmed:issn0009-7322lld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:WuYYlld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:GAYJ PJPlld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:KoweyP RPRlld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:RialsS JSJlld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:MarinchakR...lld:pubmed
pubmed-article:9286966pubmed:authorpubmed-author:FilartR ARAlld:pubmed
pubmed-article:9286966pubmed:issnTypePrintlld:pubmed
pubmed-article:9286966pubmed:day19lld:pubmed
pubmed-article:9286966pubmed:volume96lld:pubmed
pubmed-article:9286966pubmed:ownerNLMlld:pubmed
pubmed-article:9286966pubmed:authorsCompleteYlld:pubmed
pubmed-article:9286966pubmed:pagination1330-6lld:pubmed
pubmed-article:9286966pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:meshHeadingpubmed-meshheading:9286966-...lld:pubmed
pubmed-article:9286966pubmed:year1997lld:pubmed
pubmed-article:9286966pubmed:articleTitleRegression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation.lld:pubmed
pubmed-article:9286966pubmed:affiliationCardiovascular Division, The Lankenau Hospital and Medical Research Center, Wynnewood, Pa 19096, USA.lld:pubmed
pubmed-article:9286966pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9286966lld:pubmed